Technical Analysis for LGVN - Longeveron Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.66 | -1.19% | -0.02 |
Earnings due: May 14
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | -1.19% | |
NR7 | Range Contraction | -1.19% | |
NR7-2 | Range Contraction | -1.19% | |
Narrow Range Bar | Range Contraction | -1.19% | |
Wide Bands | Range Expansion | -1.19% | |
Oversold Stochastic | Weakness | -1.19% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 16 hours ago |
New 52 Week Low | about 19 hours ago |
10 DMA Resistance | about 21 hours ago |
Down 3% | about 21 hours ago |
Fell Below Previous Day's Low | about 21 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/14/2024
Longeveron Inc. Description
Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Stem Cell Cell Therapy Cell Biology Acute Respiratory Distress Syndrome Mesenchymal Stem Cell Alzheimer’s Disease
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 40.0 |
52 Week Low | 1.6 |
Average Volume | 2,662,334 |
200-Day Moving Average | 14.86 |
50-Day Moving Average | 3.15 |
20-Day Moving Average | 1.94 |
10-Day Moving Average | 1.71 |
Average True Range | 0.38 |
RSI (14) | 37.89 |
ADX | 36.83 |
+DI | 33.52 |
-DI | 19.65 |
Chandelier Exit (Long, 3 ATRs) | 3.11 |
Chandelier Exit (Short, 3 ATRs) | 2.74 |
Upper Bollinger Bands | 2.85 |
Lower Bollinger Band | 1.02 |
Percent B (%b) | 0.35 |
BandWidth | 94.67 |
MACD Line | -0.42 |
MACD Signal Line | -0.50 |
MACD Histogram | 0.0822 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.83 | ||||
Resistance 3 (R3) | 1.82 | 1.77 | 1.80 | ||
Resistance 2 (R2) | 1.77 | 1.72 | 1.77 | 1.79 | |
Resistance 1 (R1) | 1.71 | 1.70 | 1.69 | 1.72 | 1.78 |
Pivot Point | 1.66 | 1.66 | 1.64 | 1.66 | 1.66 |
Support 1 (S1) | 1.60 | 1.61 | 1.58 | 1.61 | 1.54 |
Support 2 (S2) | 1.55 | 1.59 | 1.55 | 1.53 | |
Support 3 (S3) | 1.49 | 1.55 | 1.52 | ||
Support 4 (S4) | 1.50 |